Skip to main content

Grafa News and Videos — Page 921

Grafa Headlines

Latest

Grafa

Why medical imaging innovators are racing for regulatory clearance

  • 4DMedical (ASX:4DX) secured Australian therapeutic approval for its non-contrast lung imaging software platform.
  • The affected software providers operate with contrasting financial profiles, ranging from $5.9 million to $628 million in annual revenues.
  • Securing government healthcare reimbursement and international commercial distribution models remains the primary strategy for the sector.
Read more: Why medical imaging innovators are racing for regulatory clearance
Grafa
Insights

How escalating artificial intelligence hardware demand is rewriting memory chip valuations

  • Micron Technology reported $41.46 billion in quarterly revenue as the firm capitalized on surging data center component demand.
  • The semiconductor manufacturer recorded a GAAP net income of $28.24 billion and declared a quarterly dividend of $0.15 per share.
  • Global hardware manufacturers must carefully secure raw materials to execute aggressive revenue projections amid volatile enterprise capital expenditures.
Read more: How escalating artificial intelligence hardware demand is rewriting memory chip valuations
Grafa
Insights

Australia’s tax overhaul shifts capital to new builds

  • The federal government has secured the passage of its first budget tax reform tranche by forming a Senate alliance with the Australian Greens.
  • The structural compromise removes a 50% capital gains tax discount, introduces cost base indexation, and applies a 30% minimum capital gains tax from July 1, 2027.
  • A strict ban on self-managed super funds borrowing for residential property shifts structural momentum towards major commercial builders of new housing supply.
Read more: Australia’s tax overhaul shifts capital to new builds
Grafa
Insights

How global delivery networks are quietly sacrificing scale to protect operational margins

  • FedEx reported $25 billion in fourth-quarter fiscal 2026 revenue while executing a spin-off of its freight division to consolidate core operations.
  • The logistics provider exceeded cost-cutting targets by securing over $1 billion in structural savings and achieving an adjusted earnings per share of $6.60.
  • Global transportation firms face mounting pressure to offset mixed profitability trends by heavily reducing capital spending and divesting secondary business units.
Read more: How global delivery networks are quietly sacrificing scale to protect operational margins
Grafa
Insights

Why dominant pharmaceutical firms are paying billion-dollar premiums for immunology assets

  • AbbVie agreed to acquire Apogee Therapeutics in a $10.9 billion all-cash transaction, paying a 60% premium to secure a late-stage immunology pipeline.
  • The company will pay $135.11 per share, with executives projecting the deal will not become accretive to adjusted earnings until 2032.
  • Large pharmaceutical manufacturers face intense capital pressure to acquire unproven, long-acting biologics to offset impending revenue losses from patent expirations.
Read more: Why dominant pharmaceutical firms are paying billion-dollar premiums for immunology assets

GET YOUR GRAFA EDGE NOW

We'll switch on a 30-day Edge trial as a welcome gift